{
      "Rank": 178,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)",
            "Control Group: Using basic contrast ."
      ],
      "ArmGroupInterventionName": [
            "Biological: Peripheral iv"
      ],
      "ArmGroupLabel": [
            "Treatment Group",
            "Control Group"
      ],
      "ArmGroupType": [
            "Experimental",
            "No Intervention"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03826433"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.\nObserve the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat.\nExplore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis."
      ],
      "BriefTitle": [
            "hUC Mesenchymal Stem Cells (19#iSCLife\u00ae-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis"
      ],
      "CentralContactEMail": [
            "georgeguo@sclnow.com",
            "xgfan@hotmail.com"
      ],
      "CentralContactName": [
            "Lei Guo, doctor",
            "Xuegong Fan, doctor"
      ],
      "CentralContactPhone": [
            "861064368977",
            "86731-84327392"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "June 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Hepatitis B"
      ],
      "ConditionAncestorId": [
            "D000008107",
            "D000004066",
            "D000006525",
            "D000014777",
            "D000007239",
            "D000004769",
            "D000010850",
            "D000012327",
            "D000086982",
            "D000003141",
            "D000018347",
            "D000004266",
            "D000010335"
      ],
      "ConditionAncestorTerm": [
            "Liver Diseases",
            "Digestive System Diseases",
            "Hepatitis, Viral, Human",
            "Virus Diseases",
            "Infections",
            "Enterovirus Infections",
            "Picornaviridae Infections",
            "RNA Virus Infections",
            "Blood-Borne Infections",
            "Communicable Diseases",
            "Hepadnaviridae Infections",
            "DNA Virus Infections",
            "Pathologic Processes"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC06",
            "All",
            "BC23"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Digestive System Diseases",
            "All Conditions",
            "Symptoms and General Pathology"
      ],
      "ConditionBrowseLeafAsFound": [
            "Hepatitis B",
            "Hepatitis",
            "Hepatitis",
            "Cirrhosis"
      ],
      "ConditionBrowseLeafId": [
            "M8747",
            "M8744",
            "M8743",
            "M10255",
            "M7637",
            "M10259",
            "M8035",
            "M6407",
            "M8762",
            "M16674",
            "M9435",
            "M5520",
            "M7082",
            "M12897",
            "M14301",
            "M2595",
            "M19640",
            "M6594"
      ],
      "ConditionBrowseLeafName": [
            "Hepatitis B",
            "Hepatitis A",
            "Hepatitis",
            "Liver Cirrhosis",
            "Fibrosis",
            "Liver Diseases",
            "Gastrointestinal Diseases",
            "Digestive System Diseases",
            "Hepatitis, Viral, Human",
            "Virus Diseases",
            "Infections",
            "Communicable Diseases",
            "Enterovirus Infections",
            "Picornaviridae Infections",
            "RNA Virus Infections",
            "Blood-Borne Infections",
            "Hepadnaviridae Infections",
            "DNA Virus Infections"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000006506",
            "D000006509",
            "D000006505",
            "D000005355"
      ],
      "ConditionMeshTerm": [
            "Hepatitis A",
            "Hepatitis B",
            "Hepatitis",
            "Fibrosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "This experimental use umbilical cord mesenchymal stem cells in treatment of decompensated hepatitis B cirrhosis to evaluate its safety and efficacy,\n\nThis experimental is mainly aimed at people aged 18-60 years old, regardless of gender and with body mass index (BMI) between 19-25kg/m2 (including boundary value). It was decided into treatment group and control group to evaluate the effectiveness and safety of mesenchymal stem cells by peripheral intravenous injection."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAge 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg/m2, including boundary value;\nThe diagnosis of hepatitis B cirrhosis was in line with the 2015 American society of hepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and the liver function grade was child-pugh B or child-pugh C, with a score range of 7-12 points, and Model for End-Stage Liver Disease score\u226421 points.\nHave not received stem cell therapy in the recent 6 months;\nSubjects will be able to sign the informed consent in accordance with the study procedures and instructions.\n\nExclusion Criteria:\n\nInsufficiency of vital organs, such as heart, kidney and lung;\nEnd-stage cirrhosis with severe complications, including but not limited to: hepatic encephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites, etc.\nConcomitant peritonitis, pneumonia, or other types of infection not under control;\nHave a history of severe allergic reaction or allergy to two or more kinds of food or medicine;\nPositive serum HIV antibody and syphilis antibody;\nAlpha fetoprotein>400ng/mL with primary liver cancer or without imaging evidence;\nChronic liver disease and cirrhosis are caused by non-chronic hepatitis B virus infection, or other factors except chronic hepatitis B virus infection ;\nPatients with severe mental illness and cognitive impairment;"
      ],
      "EnrollmentCount": [
            "20"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Treatment Group"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "6*10^7 cells"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Peripheral iv"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Hepatitis B Cirrhosis, mesenchymal stem cell"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "July 22, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "July 20, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Sclnow Biotechnology Co., Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Changsha"
      ],
      "LocationContactEMail": [
            "xgfan@hotmail.com"
      ],
      "LocationContactName": [
            "ShaLing Li, doctor",
            "Xuegong Fan, doctor"
      ],
      "LocationContactPhone": [
            "8613975186154",
            "86731-84327392"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Xiangya Hospital Central South University"
      ],
      "LocationState": [
            "Hunan"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "410008"
      ],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-LC) in the Treatment of Decompensated Hepatitis b Cirrhosis"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Sclnow Biotechnology Co., Ltd."
      ],
      "OrgStudyId": [
            "SCLnow-XY-04"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [
            "After finish the mesenchymal stem cell treatment, observe the change of Prothrombin Time and International Normalized Ratio (PT/INR) in baseline outcome measures.\n\nThe time is around 12-13 seconds, the INR in absence of anticoagulation therapy is 0.8-1.2.",
            "After finish the mesenchymal stem cell treatment, observe the Computed Tomography (CT).",
            "Fibro-Touch examination",
            "To evaluate the changes of safety indexes before and after mesenchymal stem cell treatment"
      ],
      "OtherOutcomeMeasure": [
            "Validity evaluation by detection of the coagulation function of participants",
            "Imaging examination",
            "Imaging examination",
            "Safety evaluation by detecting adverse events and serious adverse events"
      ],
      "OtherOutcomeTimeFrame": [
            "12 month",
            "12 month",
            "12 month",
            "12 month"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Xiangya Hospital of Central South University"
      ],
      "OverallOfficialName": [
            "Xuegong Fan, doctor"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "After finish the mesenchymal stem cell treatment, observe the change in baseline outcome measures.\n\n40 or more - 71.3% observed mortality 30-39 - 52.6% observed mortality 20-29 - 19.6% observed mortality 10-19 - 6.0% observed mortality <9 - 1.9% observed mortality"
      ],
      "PrimaryOutcomeMeasure": [
            "Validity evaluation by detection of the Model for end-stage Liver Disease score of participants"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 month"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "To calculate the number of hemocyte and related protein (e.g. erythrocyte, lymphocyte, and hemoglobin) after mesenchymal stem cell treatment",
            "After finish the mesenchymal stem cell treatment, observe the change in baseline outcome measures.\n\nPoints Class One-year survival Two-year survival 5-6 A 100% 85% 7-9 B 80% 60% 10-15 C 45% 35%"
      ],
      "SecondaryOutcomeMeasure": [
            "Safety evaluation by detecting Blood routine",
            "Validity evaluation by detection of the child-pugh of participants"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 month",
            "12 month"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "October 1, 2018"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "February 1, 2019"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "January 14, 2019"
      ],
      "StudyFirstSubmitQCDate": [
            "January 30, 2019"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}